Manufacturing of a Dissolving Microneedle Patch to Administer Rotavirus Vaccine

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

CDC OFFICE OF ACQUISITION SERVICES

Contract Value

Not provided

Codes & Classification
Solicitation Number

CDC-75D301-Presolicitation-MfgDMNPatch

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

B599

Additional Details
Set Aside

None

Place of Performance

Atlanta, Georgia, UNITED STATES

SourceSAM
The Centers for Disease Control and Prevention (CDC), through its National Center for Immunizations and Respiratory Diseases (NCIRD), has issued a Special Notice indicating its intent to award a sole source, firm fixed price contract to Micron Biomedical Incorporated, located at 311 FERST Drive NW STE L1309, Atlanta, Georgia. This procurement is not open for competitive quotes, as it is being conducted under the authority of FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1), which allows for sole source awards when only one responsible source is capable of fulfilling the agency’s requirements. The primary objective of this procurement is the manufacturing of a dissolving microneedle (MN) patch designed to administer a live attenuated rotavirus vaccine. The intended outcome is to produce these specialized patches for use in a planned clinical trial, supporting CDC’s ongoing efforts to advance immunization technologies and improve vaccine delivery methods. The scope of work is focused specifically on the production of these microneedle patches, which are expected to meet stringent quality and performance standards suitable for clinical evaluation. The period of performance for this contract is set from April 15, 2026, through April 14, 2028. The anticipated award date is on or before April 24, 2026. The applicable North American Industry Classification System (NAICS) code for this requirement is 541715, which covers Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology). The Product Service Code (PSC) associated with this notice is B599. The place of performance for this contract is Atlanta, Georgia, United States. The contracting activity is managed by the CDC Office of Acquisition Services, a federal office within the Department of Health and Human Services. While this is a notice of intent to award on a sole source basis, the CDC is inviting interested parties to submit capability statements. These statements must provide detailed management and technical data, as well as cost information, demonstrating the ability to meet the CDC’s requirements for manufacturing the dissolving microneedle patch and providing necessary warranties and proof of capability. Submissions are limited to two pages (8.5 x 11 inches, minimum 10-point font) and must be sent via email as a Microsoft Word or Adobe PDF attachment to Tim Williams at [email protected] by 10:00 AM Eastern Standard Time on April 8, 2026. No telephone requests or offers will be honored, and requests for additional information or documentation will not be considered as affirmative responses. The CDC will review all capability statements received by the deadline to determine whether to proceed with the sole source award or to consider a competitive procurement. The final decision rests solely with the government. For further information, interested parties may refer to the official notice on SAM.gov (Opportunity ID: 16934270edcf489dbde54d9b68382283) or contact the primary point of contact, Tim Williams, at [email protected] or 770-488-2791. This procurement represents a specialized opportunity for entities with proven expertise in the development and manufacturing of advanced vaccine delivery systems, particularly dissolving microneedle technologies, to support a critical public health initiative.